AMCP Regulatory NewsBreaks
Regulatory NewsBREAK

Feb. 9, 2023: CMS Posted Information Collection Materials for the New Manufacturer Discount Program

The Inflation Reduction Act (IRA) requires the establishment of a new Medicare Part D manufacturer discount program (MDP) beginning Jan. 1, 2025 and requires participating manufacturers to enter into agreements with CMS by Mar. 1, 2024 in order to participate in the MDP in 2025. Agreements will be valid for not less than one year and automatically renew unless terminated by CMS or the manufacturer.
AMCP Regulatory NewsBreaks
Regulatory NewsBREAK

Feb. 6, 2023: CMS Released the RADV Final Rule

On Feb. 1, the Final Rule, titled Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of AllInclusive Care for the Elderly (PACE), Medicaid Fee-For-Service, and Medicaid Managed Care Programs for Years 2020 and 2021, was published in the Federal Register.
AMCP Podcast Series Featured Episode
Podcast

Passing the PIE Act: Importance to Payers and Patients

Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up!, sits down with Susan Cantrell, AMCP CEO, to discuss the significance of the recent passage of the Pre-approval Information Exchange (PIE) Act of 2022.
AMCP Legislative Days
Blog

The PIE Act: A Case Study in the Importance of Persistence in Policymaking

In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
Pre-Approval Information Exchange, Legislation & Regulation
Chronic Lymphocytic Leukemia thumbnail
Resource

JMCP Outsert - CLL (BTKis)

Recommendations for treatment initiation in CLL are stratified by disease stage using either the Rai staging system, which defines disease as low-, intermediate-, or high-risk; or the Binet staging system, which defines disease as stage A, B, or C based on the number of lymphoid areas involved and the presence of anemia or thrombocytopenia. Generally, treatment should be initiated in patients with active or progressive disease who are intermediate- or high-risk, or stage B or C.
Market Insights, Cancer – Chronic Lymphocytic Leukemia